Targeted treatment with somatostatin analogues: widening horizons of clinical practice

Targeted treatment with somatostatin analogues (SA) in acromegaly and neuroendocrine neoplasms may have some benefits compared to curative treatments, because these agents decrease excessive hormone secretion exert a tumor-suppressive effect. Monotherapy combination therapy SA is well tolerated bears no risk of debilitating iatrogenic complications. In caused by somatotropin producing pituitary tumor, first generation are choice after non-radical adenomectomy, as the cases when patients reject surgery. Treatment efficacy depends on pathomorphological types somatotropic tumors, which different their receptor phenotype, clinical scenario proliferative activity. The successfully used for medical other tumors (thyrotropic, corticotropic, gonadotropic, lactotropic resistance dopamine agonists), adjuvant non-endocrine elimination various gastrointestinal disorders. anti-secretory anti-tumor effects been proven gastroenteropancreatic (carcinoid syndrome, vipomas, gastrinomas, insulinomas, glucagonomas, somatostatinomas). selection based phenotypes malignant cells would facilitate more rapid achievement biochemical remission, improvement quality life survival.